{"entity":{"id":"nct06612281","kind":"trial","name":"Evaluation of Gixam's Performance in a FIT Negative Population","aka":[],"tldr":"A phase 2 trial of colorectal cancer (CRC) screening in colorectal cancer, run by Jubaan Ltd., now recruiting.","summary":"Evaluation of Gixam's Performance in a FIT Negative Population is a phase 2 interventional study registered as NCT06612281 by Jubaan Ltd., with 400 participants planned, started 2024-11-01 and due to reach its primary completion in 2025-03-30. Interventions recorded: colorectal cancer (CRC) screening and Colonoscopy after bowel cleansing.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06612281","url":"https://clinicaltrials.gov/study/NCT06612281"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06612281","phase":"2","setting":"Evaluation of Gixam's Performance in a FIT Negative Population","sponsor":"Jubaan Ltd.","enrolled":400,"outcomes":[]},"route":"/trials/nct06612281/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}